ClearPoint Neuro announced preliminary, unaudited financial results for its fourth quarter and full year ended December 31…Preliminary unaudited revenue of approximately $6.8M a 32% year-over-year increase; Increased biologics and drug delivery revenue to approximately $4.1M, a 76% year-over-year increase; and Cash burn of approximately $1.2Mn the fourth quarter. The Company had approximately $23.1 M in cash and cash equivalents at December 31.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CLPT:
- ClearPoint Neuro Reports Fourth Quarter and Full Year 2023 Preliminary Revenue Results and Guidance for Full Year 2024 Revenue
- ClearPoint Neuro transferred with a Buy at B. Riley
- Lake Street medical devices analysts hold an analyst/industry conference call
- ClearPoint Neuro price target lowered to $11 from $15 at Lake Street
